#14a Da) 3/23/02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HORTON et al.

Appl. No. 09/557,907

Filed: April 21, 2000

**Treatment of Cancer Using** 

Cytokine-Expressing

Polynucleotides and Compositions

Therefor

Confirmation No.: 9397

Art Unit: 1633

Examiner: Wilson, M

Atty. Docket: 1530.0060004/EKS/EJH



Amendment And Reply Under 37 C.F.R. § 1.11

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Office Action dated **December 19, 2001**, (PTO Prosecution File Wrapper Paper No. 13), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of